US · ILMN
Illumina, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- San Diego, CA 92122
- Website
- illumina.com
Price · as of 2025-12-28
$135.78
Market cap 20.56B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $114.40 | -15.75% |
| Intrinsic Value(DCF) | $58.96 | -56.58% |
| Graham-Dodd Method(GD) | $38.30 | -71.79% |
| Graham Formula(GF) | $41.98 | -69.08% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $9.62 | $17.12 | |||
| 2012 | $13.87 | $20.35 | |||
| 2013 | $11.49 | $30.95 | |||
| 2014 | $18.48 | $98.49 | |||
| 2015 | $23.47 | $84.34 | |||
| 2016 | $25.90 | $49.67 | |||
| 2017 | $39.06 | $110.82 | |||
| 2018 | $48.60 | $159.63 | |||
| 2019 | $59.86 | $97.15 | |||
| 2020 | |||||
| 2021 | $48.14 | $0.00 | |||
| 2022 | $49.58 | $234.70 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $86.62 | $47.44 | $0.00 | $0.00 | $0.00 |
| 2025 | $132.89 | $114.40 | $9.22 | $38.30 | $41.98 |
AI valuation
Our deep-learning model estimates Illumina, Inc.'s (ILMN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $114.40
- Current price
- $135.78
- AI upside
- -15.75%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$58.96
-56.58% upside
Graham-Dodd
$38.30
-71.79% upside
Graham Formula
$41.98
-69.08% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ILMN | Illumina, Inc. | $135.78 | 20.56B | -16% | -57% | -72% | -69% | 23.92 | 7.47 | 4.68 | 14.59 | — | 14.52 | 66.49% | 19.92% | 19.58% | 33.36% | 18.25% | 13.13% | 0.94 | 8.65 | 2.08 | 1.57 | 0.78 | -17074.00% | -69.00% | 3131.00% | 4.58% | 0.68 | 25.10% | 0.00% | 0.00% | 5.42% | 24.57 | 22.83 | 4.89 | 4.42 |
| DGX | Quest Diagnostics Incorpo… | $211.91 | 23.57B | -3% | -58% | — | -18% | 22.31 | 3.25 | 2.11 | 13.60 | 161.86 | -6.84 | 31.93% | 14.53% | 8.99% | 15.00% | 9.14% | 6.46% | 0.96 | 6.07 | 1.04 | 0.80 | 2.96 | 1378.00% | 1178.00% | 4950.00% | 5.82% | 0.83 | 10.07% | 1.51% | 33.70% | 3.61% | 18.61 | 21.95 | 2.70 | 3.44 |
| GMAB | Genmab A/S | $29.44 | 18.14B | +21% | -15% | -44% | -6% | 19.14 | 3.16 | 4.95 | 16.85 | — | -5.09 | 91.69% | 33.60% | 25.89% | 16.63% | 16.30% | 9.62% | 0.95 | 20.49 | 2.02 | 2.01 | 2.90 | -1936.00% | 1023.00% | -336.00% | 6.23% | 0.83 | 18.73% | 0.00% | 0.00% | 2.33% | 17.81 | 19.37 | 5.98 | 2.77 |
| HOLX | Hologic, Inc. | $75.36 | 16.82B | +9% | -53% | -75% | -67% | 30.11 | 3.37 | 4.15 | 17.05 | — | 20.82 | 61.00% | 17.42% | 13.80% | 11.12% | 10.86% | 6.23% | 0.52 | 16.73 | 3.75 | 2.87 | 0.65 | -2500.00% | 174.00% | -1964.00% | 5.40% | 1.08 | 16.84% | 0.00% | 0.00% | 4.42% | 24.44 | 18.97 | 4.26 | 4.18 |
| ICLR | ICON Public Limited Compa… | $108.14 | 8.26B | +89% | -31% | -50% | -11% | 19.44 | 1.62 | 1.86 | 11.80 | 67.55 | -4.98 | 29.42% | 13.26% | 9.56% | 8.44% | 7.88% | 4.67% | 0.38 | 4.63 | 1.26 | 1.21 | 1.96 | 2878.00% | 199.00% | 963.00% | 7.27% | 0.46 | 8.81% | 0.00% | 0.00% | 6.47% | 16.81 | 16.50 | 2.23 | 2.24 |
| LH | Labcorp Holdings Inc. | $289.12 | 23.97B | -28% | -60% | -89% | -45% | 27.16 | 2.77 | 1.71 | 15.16 | 148.18 | -13.50 | 26.75% | 10.87% | 6.28% | 10.53% | 8.26% | 4.77% | 0.84 | 6.77 | 1.42 | 0.99 | 3.31 | 1833.00% | 725.00% | 1005.00% | 5.06% | 0.58 | 8.29% | 1.01% | 27.40% | 2.90% | 20.12 | 25.30 | 2.19 | 3.23 |
| MEDP | Medpace Holdings, Inc. | $451.76 | 12.82B | -29% | +273% | -84% | -6% | 29.25 | 28.75 | 5.22 | 22.70 | 139.42 | -55.74 | 30.06% | 21.14% | 17.83% | 70.23% | 171.74% | 22.13% | 0.55 | — | 0.74 | 0.67 | -0.43 | 2098.00% | 1997.00% | 1915.00% | 5.17% | 0.53 | 263.19% | 0.00% | 0.00% | 6.95% | 24.21 | 18.99 | 5.12 | 6.85 |
| THC | Tenet Healthcare Corporat… | $239.39 | 21.04B | -32% | -53% | -100% | -28% | 15.18 | 5.06 | 1.00 | 7.36 | — | -2.57 | 41.41% | 16.46% | 6.60% | 33.54% | 19.78% | 4.80% | 3.12 | — | 1.76 | 1.22 | 2.39 | -5263.00% | 312.00% | 12670.00% | 11.85% | 0.79 | 16.87% | 0.00% | 0.00% | 11.50% | 9.02 | 12.51 | 1.48 | 2.07 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
| WST | West Pharmaceutical Servi… | $254.34 | 18.32B | -20% | -57% | -75% | -62% | 36.79 | 5.72 | 5.91 | 24.59 | 2237.77 | 5.94 | 35.89% | 20.09% | 16.06% | 16.85% | 18.68% | 12.48% | 0.13 | 1029.00 | 3.02 | 2.09 | -0.52 | 164.00% | 626.00% | 6965.00% | 2.58% | 1.15 | 17.68% | 0.34% | 12.40% | 2.15% | 28.82 | 37.94 | 5.79 | 12.97 |
| ZBH | Zimmer Biomet Holdings, I… | $98.44 | 19.51B | +4% | -60% | -82% | -46% | 27.93 | 1.55 | 2.39 | 12.01 | — | -10.06 | 61.62% | 16.55% | 8.57% | 5.60% | 6.12% | 3.17% | 0.59 | 4.65 | 1.98 | 0.89 | 3.12 | -1986.00% | 720.00% | 2887.00% | 7.47% | 0.66 | 7.80% | 0.97% | 27.00% | 3.44% | 19.55 | 18.08 | 3.23 | 1.82 |
About Illumina, Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
- CEO
- Jacob Thaysen
- Employees
- 8.97K
- Beta
- 1.45
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($58.96 ÷ $135.78) − 1 = -56.58% (DCF, example).